News


All series


All News

Mario E. Lacouture, MD, has joined the Treatment Support Program of the National Community Oncology Dispensing Association as director of the medical advisory board.

According to results from the ongoing phase I/II GARNET trial, dostarlimab induced an overall response rate of nearly 30% in patients with recurrent or advanced endometrial cancer. Results presented at the 2019 SGO Annual Meeting also demonstrated durable responses in both patients with microsatellite instability-high and microsatellite stable tumors.

The establishment of a high-risk cancer screening and genetic counseling service in a community setting may be an arduous undertaking but, as demonstrated in a case study presented during the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Center Summit held in Washington, DC, it could help to reduce the chance of patients developing a hereditary cancer.

Three next-generation physician practice management companies—US Oncology Network, American Oncology Network, and OneOncology—provided an overview of their business models to distinguish themselves from competitors at a breakout session during the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Center Summit held in Washington, DC.

During a <em>Targeted Oncology </em>case-based peer perspectives program, Elias Jabbour, MD, discussed his clinical considerations for the management of chronic myeloid leukemia in chronic phase.&nbsp;Jabbour explained his treatment decisions during the live event based on a case scenario of a patient with CML-CP.

The phase III JAVELIN Ovarian PARP 100 study has been discontinued,&nbsp;according to Merck KGaA and Pfizer, the companies that collaborated on the trial.<sup>&nbsp;</sup>The ongoing trial was investigating the efficacy and safety&nbsp;of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer.

A partial clinical hold has been placed on&nbsp;all clinical trials examining venetoclax in multiple myeloma,&nbsp;according to AbbVie, co-developer of the BCL-2 inhibitor with Genentech. This hold, placed by the FDA,&nbsp;halts enrollment of new patients on the studies.

The clinical practice guidelines for the treatment of patients with colorectal cancer have been updated by NCCN to include the combination of&nbsp;encorafenib plus binimetinib in addition to EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with <em>BRAF</em> V600E&ndash;mutant metastatic CRC, after 1 or 2 prior therapies for metastatic disease.

Following a recommendation from the&nbsp;Oncologic Drugs Advisory Committee against the accelerated approval of&nbsp;selinexor for the treatment of patients with penta-refractory multiple myeloma, the FDA has added&nbsp;3 months to the review period for the new drug application,&nbsp;making the new action date July 6, 2019.